Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label consolidation nivolumab after concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma
KCT0006188Phase 2Recruiting
- Sponsor
- Yonsei University Health System
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by Yonsei University Health System. Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on KCT0006188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006188.